Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | NVP-231 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.027 | 0.7 |
mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | BRD1835 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | MG-132 | GDSC1000 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | BRD1812 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | SL 0101-1 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.7 |